Michael Nagel is an accomplished executive in medical technology, driving innovation in infection control and wound healing as President and CEO of Vomaris Innovations, Inc. Under his leadership, the company has advanced V.Dox™ Technology, a bioelectric solution designed to enhance healing at the cellular level. His strategic direction has secured key funding, partnerships, and regulatory milestones, positioning Vomaris at the forefront of bioelectric medicine. In addition to his role at Vomaris, Michael contributes to cutting-edge healthcare advancements as an observer on the board of VenoStent, Inc., which is pioneering biomaterial solutions for hemodialysis patients. He also serves as Chairman of the Board at Kiromic Biopharma, Inc., a biotechnology company leveraging AI for immuno-oncology breakthroughs. Michael holds an MBA in New Ventures and a BA in Business from the University of Saint Thomas – School of Business. His expertise spans medical technology, cardiology, and biotechnology, positioning him as a key innovator in healthcare advancements.

Please schedule a time with our support team, and we will help you arrange a consultation with the educator.